Bringing Hope to Young Lives: Advanced Cancer Treatment at Bioocus Medical Group

At Bioocus Medical Group, we are committed to delivering cutting-edge cellular and gene therapies to patients worldwide. A compelling example of this dedication is Emin, an 8-year-old boy from Russia, currently receiving treatment for Stage IV neuroblastoma at our Cellular and Gene Therapy (CGT) Center in Tianjin Cancer Hospital Airport Hospital.

Understanding Neuroblastoma

Neuroblastoma is a aggressive cancer that originates in the sympathetic nervous system and predominantly affects young children. In its advanced Stage IV form, the disease spreads to distant sites such as bones, bone marrow, and lymph nodes, posing significant treatment challenges. Emin’s journey began in March 2020 with a diagnosis confirmed in May of that year. Despite undergoing extensive treatments—including surgery, multiple chemotherapy cycles, autologous and allogeneic stem cell transplants, and differentiation therapy—his condition continued to relapse, prompting his family to seek our specialized care.

Pioneering GD2 CAR-T Therapy

Upon Emin’s arrival, our expert team conducted a thorough evaluation and recommended GD2 CAR-T therapy, a groundbreaking Immunotherapy tailored for neuroblastoma. This innovative treatment involves:

1. T-Cell Collection: Extracting Emin’s T cells via leukapheresis.

2. Genetic Modification: Engineering these T cells in our advanced laboratories to express chimeric antigen receptors (CARs) targeting the GD2 antigen, highly expressed on neuroblastoma cells.

3. Infusion: Returning the modified CAR-T cells to Emin’s body to attack the cancer.

This personalized approach harnesses the patient’s own immune system, offering new hope for cases resistant to conventional therapies. The treatment, spanning 6-8 weeks, is supported by our state-of-the-art facilities and may include adjuvant therapies like natural killer (NK) cell therapy or dendritic cell (DC) vaccines, depending on Emin’s post-infusion immune response.

Our Expertise and Comprehensive Care

Bioocus Medical Group stands at the forefront of Cancer Treatment, with four CGT centers strategically located in top oncology and hematology hospitals across Beijing and Tianjin. Our Tianjin center, where Emin is being treated, exemplifies our commitment to excellence. Our multidisciplinary team—comprising oncologists, immunologists, and cellular therapy specialists—brings unparalleled expertise to every case. We prioritize patient safety, vigilantly monitoring for side effects like cytokine release syndrome and providing immediate, expert management when needed.

Our services extend beyond medical innovation. We offer a full spectrum of care, from initial assessments to post-treatment follow-ups, ensuring a seamless experience. For international patients like Emin, we provide culturally sensitive support, helping families navigate their journey far from home with confidence and comfort.

A Global Mission of Hope

Emin’s story underscores our ability to serve patients globally, reflecting the trust families place in our advanced therapies and professional care. As he continues his treatment, our team remains dedicated to optimizing his plan, adapting to his unique needs, and exploring every avenue to combat this relentless disease.

At Bioocus Medical Group, we believe every child deserves a fighting chance. Through our relentless pursuit of innovation and compassionate care, we aim to transform lives—one patient at a time.